enGene Therapeutics (ENGN) Net Cash Flow (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Net Cash Flow of -$6.8 million for Q2 2026, down 41.41% year-over-year from -$11.6 million in Q2 2025, and up 49.85% quarter-over-quarter from -$13.5 million in Q1 2026.
enGene Therapeutics (ENGN) Net Cash Flow (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Net Cash Flow for 4 consecutive years, with -$6.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow fell 41.41% year-over-year to -$6.8 million; the TTM figure through Apr 2026 stood at -$27.7 million (up 86.63% YoY), while the FY2025 annual figure was -$122.9 million, down 234.29% from the prior year.
- Net Cash Flow grew to -$6.8 million in Q2 2026 per ENGN's latest filing, from -$13.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $179.2 million in Q2 2024 and bottomed at -$110.7 million in Q1 2025.
- Historically, Net Cash Flow has averaged $670642.9 across 4 years, with a median of -$5.5 million in 2023.
- Annual changes were most pronounced in 2024 — Net Cash Flow jumped 5314.45% — and 2025, when it tumbled 2783.29%.
- enGene Therapeutics' Net Cash Flow stood at $43.9 million in 2023, then tumbled by 292.76% to -$84.7 million in 2024, then soared by 120.7% to $17.5 million in 2025, then tumbled by 138.73% to -$6.8 million in 2026.
- Business Quant data shows ENGN's Net Cash Flow at -$6.8 million in Q2 2026, -$13.5 million in Q1 2026, and $17.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -6.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -6.79 Mn |
| Apr 30, 2026 | -6.79 Mn |
| Jan 31, 2026 | -13.54 Mn |
| Jan 31, 2026 | -13.54 Mn |
| Oct 31, 2025 | 17.53 Mn |
| Oct 31, 2025 | 17.53 Mn |
| Jul 31, 2025 | -24.92 Mn |
| Jul 31, 2025 | -24.92 Mn |
| Apr 30, 2025 | -4.80 Mn |
| Apr 30, 2025 | -4.80 Mn |
| Jan 31, 2025 | -110.66 Mn |
| Jan 31, 2025 | -110.66 Mn |
| Oct 31, 2024 | -84.67 Mn |
| Oct 31, 2024 | -84.67 Mn |
| Jul 31, 2024 | -7.13 Mn |
| Jul 31, 2024 | -7.13 Mn |
| Apr 30, 2024 | 179.16 Mn |
| Apr 30, 2024 | 179.16 Mn |
| Jan 31, 2024 | 4.12 Mn |
| Jan 31, 2024 | 4.12 Mn |